Pathological aspects of immunization of mice against influenza virus infection
- PMID: 1106747
- PMCID: PMC2072713
Pathological aspects of immunization of mice against influenza virus infection
Abstract
Groups of mice were immunized against influenza Ao/NWS virus by a single intranasal administration of inactivated homologous virus, by 2 intranasal doses of vaccine separated by an interval of 2 weeks, or by 2 intraperitoneal doses of the same vaccine. When subjected 2 weeks later to a standard challenge of 6 x 10(5) egg infecting units Ao/NWS virus instilled intranasally, mortality fell significantly from 64% in unimmunized mice to 39% in mice given a single intranasal dose of vaccine and to 29% in animals which received double intranasal vaccine. The best protection was conferred by double intraperitoneal immunization, after which mortality was 10%. Immunity waned with time, since the mortality of mice doubly immunized by the respiratory route and challenged 30 weeks later was 49%. Intrapulmonary lymphoid tissue developed in large amounts in a proportion of mice immunized by all methods and challenged after an interval of 2 weeks. Attention is drawn to this reaction as a possible unfavourable consequence of vaccination. There were no lesions in the lungs or central nervous system after immunization without subsequent challenge. The importance of histopathology in vaccine trials in experimental animals is emphasized by the consistently higher detection rate of lesions in lungs by histological examination than by visual inspection alone.
Similar articles
-
Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10. Virology. 2008. PMID: 18786689
-
Assessment of resistance to influenza virus infection in animal models.Dev Biol Stand. 1975;28:307-18. Dev Biol Stand. 1975. PMID: 1126574
-
Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.J Med Virol. 2006 Jul;78(7):954-63. doi: 10.1002/jmv.20647. J Med Virol. 2006. PMID: 16721854
-
Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine.Eur J Immunol. 1992 Feb;22(2):477-81. doi: 10.1002/eji.1830220228. Eur J Immunol. 1992. PMID: 1537382
-
Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.Vaccine. 2010 Nov 10;28(48):7690-8. doi: 10.1016/j.vaccine.2010.09.019. Epub 2010 Sep 24. Vaccine. 2010. PMID: 20870054
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical